Transforming the Pharmaceutical Industry
through Innovation

News and Events


Galt Pharmaceuticals® Answers the Call for Better Practices in Pain Management with a Non-opioid Therapeutic Alternative

May 29, 2019

Officials with the FDA have given Priority Review designation to an opioid-free pain management treatment from Galt Pharmaceuticals®.

According to the company, its Supplemental Abbreviated New Drug Application for the orphenadrine citrate, aspirin and caffeine combination (Orphengesic Forte), a muscle relaxant pain reliever, was given an August 2019 goal for approval.

“Health care providers simply need more choices as they look for noncontrolled opioid free alternatives for pain management and our goal is to offer 1 more proven alternative before prescribing an opioid or controlled medication,”¬†said Galt CEO and co-founder Barry Patel, PharmD.

Galt's request for approval of its combination pain reliever supports the call for opioid addiction prevention by the Center for Medicare and Medicaid Services, according to the company. One of the Center's key focuses is to manage pain using a safe and effective range of treatment options that rely less on prescription opioids.

Share the resource:

Share on Facebook Share on Twitter Share on LinkedIn